...
首页> 外文期刊>Medicinal Chemistry >Synthesis of 3-Isopropylbenzo[D]Oxazol-2(3H)-One Amides and UreaDerivatives; Evaluation of their Anti-Mycobacterial and Cytotoxic Activity
【24h】

Synthesis of 3-Isopropylbenzo[D]Oxazol-2(3H)-One Amides and UreaDerivatives; Evaluation of their Anti-Mycobacterial and Cytotoxic Activity

机译:3-异丙基苯并[D] Oxazol-2(3H)-1酰胺和脲衍生物的合成;评估其抗分枝杆菌和细胞毒活性

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Tuberculosis (TB) is a traditional disease caused by infection with Mycobacterium tuberculosis, it is a serious public health issue due to its risk of person-to-person transmission, and high level of morbidity and humanity. The World Health Organization (WHO) estimates 11.4 million people worldwide are infected with both Mycobacterium tuberculosis (Mtb) and HIV. Currently, there are approximately 8 million new infections and 3 million deaths attributed to M. tuberculosis annually. One of the major problems associated in comprehensive control of TB is that the restart of the disease in patients who carry a latent syndrome, in which the bacteria is in slow budding or non growing state and is refractory to treat with predictable anti-TB drugs. Directly observed treatment (DOT) is presently practicing for standard TB chemotherapy. It is well known that the resistance levels are poor in the areas with a strongly performing DOTS programmes. However, various drugs available in the market cannot be used for prolonged times due to diverse side effects. Therefore, the development of new and safe anti-TB drugs is in high demand. The major investigation on sEH inhibitors focused on urea, amide, amino- heterocycles and carbamate derivatives, but research on new compound structures is limited. Benzoxazolones are widely distributed in plants and are of increasing interest for a variety of pharmacological properties, such as detoxification, antibacterial, anti- HIV, anti-inflammatory, and transequilizers. Since benzoxazolones are active and inexpensive, many structural modification and preliminary bioactivity evaluation studies have been performed based on benzoxazol-ones. In this paper, 3-isopropyl benzo[d]oxazol-2(3H)-one amides and urea analogues were synthesized and evaluated as sEH inhibitors in vitro, and their anti-tuberculosis activities were determined in vivo. The 3-isopropylbenzo[d]oxazol- 2(3H)-one heterocycles has received considerable attention from the medicinal chemists owing to their capacity to mimic a benzamides or a phenyl urea moiety in a metabolically stable template. This class of compounds has led to the discovery of a number of derivatives endowed with antibacterial-antifungal, analgesic-antiinflammatory, anticonvulsant, dopaminergic, HIV-1 reverse transcriptase activity, and normolipenic agents. Usually functionalization of the nitrogen atom is of interest, since the electronic characteristic of this atom can be decisive for the biological activity. Nevertheless, most efforts have focused on N-, 5-, or 6-substituted benzoxazol-ones. Presently, 5-substituted benzoxazolone derivatives have been scarcely prepared, and few reports have described the sEH inhibitory activities or anti-tuberculosis activities. The pronounced biological activity of benzoxazolone derivatives and the lack of structure-bioactivity relationships prompted our investigation on 5-substituted-3- isopropylbenzo[d]oxazol-2(3H)-one.
机译:结核病(TB)是由结核分枝杆菌感染引起的传统疾病,由于它具有人与人之间传播的风险以及较高的发病率和人类性,因此是一个严重的公共卫生问题。世界卫生组织(WHO)估计,全球有1140万人同时感染了结核分枝杆菌(Mtb)和HIV。目前,每年约有800万新感染和300万死于结核分枝杆菌。全面控制结核病的主要问题之一是携带潜伏综合征的患者的疾病重新发作,其中细菌处于缓慢出芽或非生长状态,并且难以用可预测的抗结核药物治疗。直接观察疗法(DOT)目前正在用于标准结核病化疗。众所周知,在执行强有力的DOTS计划的地区,抵抗力水平很差。然而,由于各种副作用,市场上可买到的各种药物不能长时间使用。因此,迫切需要开发新的,安全的抗结核药物。 sEH抑制剂的主要研究集中在尿素,酰胺,氨基杂环和氨基甲酸酯衍生物上,但是对新化合物结构的研究是有限的。苯并恶唑啉酮广泛分布于植物中,并且对多种药理特性(例如排毒,抗菌,抗HIV,抗炎药和透味药)越来越感兴趣。由于苯并恶唑酮是活性且廉价的,因此已经基于苯并恶唑酮进行了许多结构修饰和初步的生物活性评估研究。本文合成了3-异丙基苯并[d]恶唑-2(3H)-一酰胺和尿素类似物,并作为sEH抑制剂进行了体外评估,并在体内确定了它们的抗结核活性。 3-异丙基苯并[d]恶唑-2(3H)-1杂环因其在代谢稳定的模板中模拟苯甲酰胺或苯基脲部分的能力而受到药物化学家的关注。这类化合物导致发现了许多具有抗菌-抗真菌,镇痛-抗炎,抗惊厥,多巴胺能,HIV-1逆转录酶活性和降粘甲剂的衍生物。通常感兴趣的是氮原子的官能化,因为该原子的电子特性对生物活性起决定性作用。然而,大多数努力集中在N-,5-或6-取代的苯并恶唑酮上。目前,几乎没有制备5-取代的苯并恶唑酮衍生物,很少有报道描述sEH的抑制活性或抗结核活性。苯并恶唑酮衍生物的明显的生物活性和缺乏结构生物活性的关系促使我们对5-取代的3-异丙基苯并[d]恶唑-2(3H)-one进行了研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号